Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (281-290 of 442) with videos related to

Pageof 45
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 TrialDavid S Hong, Michael Postow, Bartosz Chmielowski, et al.
Frontiers in Immunology|August 19, 2022
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung CancerDavid S Hong, Ajay K Gopal, Alexander N Shoushtari, et al.
Scientific Reports|February 2, 2018
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung CancerChad Tang, Brian Hobbs, Ahmed Amer, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Practical Radiation Oncology|November 14, 2024
Best Practice Guidelines for Use of Reference Points in Radiation Oncology Information Systems to Aggregate Longitudinal Dosimetric DataAlon Witztum, Younes Jourani, Emily Y Hirata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation TrialVivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trialKanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung CancerD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Pageof 45

Showing results (281-290 of 442) with videos related to

Sort By:
Pageof 45
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 TrialDavid S Hong, Michael Postow, Bartosz Chmielowski, et al.
Frontiers in Immunology|August 19, 2022
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung CancerDavid S Hong, Ajay K Gopal, Alexander N Shoushtari, et al.
Scientific Reports|February 2, 2018
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung CancerChad Tang, Brian Hobbs, Ahmed Amer, et al.
Oncoscience|January 17, 2015
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitorsChad Tang, Denis L Fontes Jardim, Gerald S Falchook, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Practical Radiation Oncology|November 14, 2024
Best Practice Guidelines for Use of Reference Points in Radiation Oncology Information Systems to Aggregate Longitudinal Dosimetric DataAlon Witztum, Younes Jourani, Emily Y Hirata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2019
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation TrialVivek Subbiah, Pete M Anderson, Kalevi Kairemo, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trialKanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung CancerD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Pageof 45